Please login to the form below
phenytoin sodium
This page shows the latest phenytoin sodium news and features for those working in and with pharma, biotech and healthcare.
Pfizer, Flynn face reinstatement of £90m CMA fine
The case dates back to 2015, when the Competition and Markets Authority (CMA) accused the two companies of dramatically raising the price of phenytoin sodium, a drug that has been used ... It is estimated that around 50, 000 people in the UK rely on
Latest news
-
Concordia accused of overcharging NHS for thyroid drug
Last December, Pfizer and Flynn Pharma were ordered to pay £84m after being accused of charging excessive and unfair prices for anti-epilepsy treatment phenytoin sodium capsules, but have appealed the
-
Pfizer gets record £84m fine for hiking price of epilepsy drug
Pfizer's decision to ramp up the price of its epilepsy drug phenytoin sodium has earned it a record-breaking fine from the UK authorities. ... The CMA says that the NHS had no alternative but to pay the increased price for phenytoin sodium because
-
Pfizer and Flynn accused of overcharging for epilepsy drug
The probe by the Competition and Markets Authority (CMA) is focusing on phenytoin sodium, a drug that has been used to treat epilepsy for decades, which is manufactured by Pfizer but ... It is estimated that around 50, 000 people in the UK take phenytoin
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
A healthcare landscape going through seismic change
drug phenytoin sodium after it was debranded in 2012.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- AZ’s COVID-19 vaccine trial to continue after Brazilian volunteer death
- Pfizer CEO pushes back COVID-19 vaccine submission to November
- The Truth about Doctors
- Novartis scores CHMP backing for cholesterol drug Leqvio
- Moderna’s chief exec expects to have COVID-19 vaccine data in November
- AZ’s US-based COVID-19 vaccine trial could restart this week
- Eliminating pharmaceutical rebates, is this déjà vu?
- Bayer pays an initial $2bn for gene therapy firm AskBio
- Both AZ and J&J set to resume US COVID-19 vaccine trials
- AZ’s COVID-19 vaccine shows promise in younger and older adults
- Bayer's drop of the future
- Patients are ready to embrace decentralised clinical trials, are you?
PMHub
Create Health
A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...
Latest intelligence
- Eliminating pharmaceutical rebates, is this déjà vu?
- By Andrew Parece and Matthew Majewski...
- Patients are ready to embrace decentralised clinical trials, are you?
- Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
- Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
- The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
Quick links
Infographics
